Sentinel Lymph Node Imaging with a Novel Radiotracer: Preparation of 99Tcm-It-rituximab and Experimental Study

XU Bing

DOI: https://doi.org/10.3321/j.issn:1003-3289.2006.01.040

2006-01-01

Abstract:Objective To investigate the located ability of a novel sentinel lymphoscintigraphy agent, ~ 99 Tc~m-IT-Rituximab, in detecting the sentinel lymph node (SLN). Methods ~ 99 Tc~m-Rituximab was prepared indirectly via 2-iminothiolane (2-IT) conjugation and labeled with techenium-99m. The locating ability of ~ 99 Tc~m-IT-Rituximab was evaluated with biological distribution results in mice, and the influenced factors on the imaging by the injecting dosage and volume were also observed in mice. Results ~ 99 Tc~m-IT-Rituximab, with a yield of about 90%, were intact. The results of the dynamic SLN mapping showed that SLN could be seen within a wide range from 30 min to 24 h after injecting, and higher order nodes had not been visualized all the time. The results of the biodistribution showed that SLNs could be identified by the imaging agent, ~ 99 Tc~m-IT-Rituximab, successfully, the rate of uptake in 24 h was about 4.49%, while the uptake of higher echelon lymph node was close to background. SLN imaging would be influenced by the dosage and volume of radiotracer, which could both result in the decrease of SLN uptake and the increase of higher order nodes uptake. Conclusion The labeling method is simple and safe. ~ 99 Tc~m-IT-Rituximab appears to be potential and useful for clinical SLN study.